Articles tagged with: NSPH
FDA Update and Applications Awaiting Approval (CTIC NSPH, AUXL)
Cell Therapeutics, Inc. (Public, NASDAQ:CTIC) recently released their second quarter figures for 2009 and stated it was a transforming quarter for the company, in which they eliminated 44.5% of their outstanding debt. They also released …
FDA decision scheduled for Nanosphere and Advanced Life Sciences (NSPH, ADLS, INO)
In the first quarter of 2009 Nanosphere, Inc. (NSPH) filed a de novo 510(k) submission for a hereditary hemochromatosis (”HFE”) genetic test. Mutations of this HFE gene are the leading cause of an iron overload disease. Nanosphere’s test …
